
Reset all filters
01 1Airsupra
02 6Breztri
03 4Cortiment
04 1Eohilia
05 11Pulmicort
06 21Symbicort
07 5Uceris
08 1Uceris/Cortiment
09 1Ultibro Group
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 996
2019 Revenue in Millions : 1,466
Growth (%) : -32
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 2,721
2019 Revenue in Millions : 2,495
Growth (%) : 9
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 28
2019 Revenue in Millions : 2
Growth (%) : 1,300
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 8
2019 Revenue in Millions : 5
Growth (%) : 70
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 6
2019 Revenue in Millions : 11
Growth (%) : -48
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2020 Revenue in Millions : 0
2019 Revenue in Millions : 213
Growth (%) : -100
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 962
2020 Revenue in Millions : 996
Growth (%) : -3
Budesonide, Glycopyrronium, Formoterol Fumarate
Main Therapeutic Indication : Respiratory Disorders
Currency : USD
2021 Revenue in Millions : 4
2020 Revenue in Millions : 5
Growth (%) : -31